Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis

References

• (WHO) WHO. Weekly Epidemiological Update: coronavirus disease 2019 (COVID–19).
   Google Scholar
• Lai -C-C, Liu YH, Wang C-Y, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–412. .
   PubMedGoogle Scholar
• Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Res. 2020;69(6):599–606. .
   PubMed Web of Science ®Google Scholar
• Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23(8):943.
   PubMed Web of Science ®Google Scholar
• Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment. 7th edition. Beijing: China National Health Commission; 2020.
   Google Scholar
• National Institutes of Health (NIH): Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
   Google Scholar
• Research N Arthritis drugs effective in improving survival in sickest COVID-19 patients: national Institute for Health Research.
   Google Scholar
• Organization WH. Clinical management of COVID–19.
   Google Scholar
• Mehta C, Kataria S, Mehta Y. COVID Special Issue, Part I: management of Coronavirus 2019. J Cardiac Crit Care TSS. 2020;4(1):40.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Hoboken: John Wiley & Sons; 2019.
   Google Scholar
• Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24–31.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al., Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 383(24): 2333–2344. 2020. .
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux P-L, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: a Randomized Clinical Trial. JAMA Internal Medicine. 2021;181(1):32–40.
   PubMed Web of Science ®Google Scholar
• Rosas I, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. 2020.
   Google Scholar
• Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Internal Med. 2020;76:43–49.
   PubMed Web of Science ®Google Scholar
• Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa954.
   PubMedGoogle Scholar
• Wadud N, Ahmed N, Shergil M, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) acute respiratory distresssyndrome patients with Tocilizumab administration. medRxiv.  2020.
   Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. .
   PubMedGoogle Scholar
• Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study. PloS One. 2020;15(8):e0237693. .
   PubMed Web of Science ®Google Scholar
• Kimmig LM, Wu D, Gold M, et al. IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. Frontiers in medicine. 2020;7:583897.
   Google Scholar
• Maeda T, Obata R, Rizk DO D, et al. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. J Med Virol. 2021;93(1):463–471. .
   PubMed Web of Science ®Google Scholar
• Moreno-García E, Rico V, Albiach L, et al. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv. 2020.
   Google Scholar
• Martínez-Sanz J, Muriel A, Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect. 2021;27(2):238-243.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Nicolini L, Signori A. Tocilizumab and steroid treatment in patients with severe COVID-19 pneumonia. medRxiv. Preprint Posted. 2020.
   Google Scholar
• Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603–e612. .
   PubMedGoogle Scholar
• Fisher MJ, Raymundo LAM, Monteforte M, et al. Tocilizumab in the treatment of critical COVID-19 pneumonia: a retrospective cohort study of mechanically ventilated patients. Int J Infectious Dis. 2021;103:536–539.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41–51. .
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Pachón J, Carratalà J, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect. 2021;27(2), 244-252.
   Google Scholar
• Rossi B, Nguyen LS, Zimmermann P, et al. Effect of tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a case–control cohort study. Pharmaceuticals. 2020;13(10):317.
   Web of Science ®Google Scholar
• Ruiz-Antoran B, Sancho-Lopez A, Torres F . et al. Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study. Infectious diseases and therapy. 2021;10(1): 347-362.
   Google Scholar
• Tsai A, Diawara O, Nahass RG, et al. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep. 2020;10(1):1–7.
   PubMed Web of Science ®Google Scholar
• Zheng K-L, Xu Y, Guo Y-F, et al. Efficacy and safety of tocilizumab in COVID-19 patients. Aging (Albany NY). 2020;12(19):18878.
   PubMedGoogle Scholar
• Hill JA, Menon MP, Dhanireddy S, et al. Tocilizumab in hospitalized patients with COVID-19: clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol. 2021;93(4):2270–2280.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Smith JB, Gonzales EG, et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infectious Dis. 2020;99:291–297.
   PubMed Web of Science ®Google Scholar
• Kewan T, Covut F, Al–Jaghbeer MJ, et al. Tocilizumab for treatment of patients with severe COVID–19: a retrospective cohort study. EClinicalMedicine 2020;24:100418.
   PubMedGoogle Scholar
• Masiá M, Fernández-González M, Padilla S, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study. EBioMedicine 2020;60:102999.
   PubMed Web of Science ®Google Scholar
• Patel K, Gooley TA, Bailey N, et al. Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients Journal of internal medicine. 2021;289(3):430–433.
   Google Scholar
• Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18(1):1–11.
   PubMed Web of Science ®Google Scholar
• Roomi S, Ullah W, Ahmed F, et al. Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: single-center retrospective chart review. J Med Internet Res. 2020;22(9):e21758.
   PubMed Web of Science ®Google Scholar
• Canziani LM, Trovati S, Brunetta E, et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: a retrospective case–control survival analysis of 128 patients. J Autoimmun. 2020;114:102511.
   PubMed Web of Science ®Google Scholar
• Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Internal Med. 2020;76:31–35.
   PubMed Web of Science ®Google Scholar
• Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5):695.
   PubMed Web of Science ®Google Scholar
• Carvalho V, Turon R, Goncalves B, et al. Effects of tocilizumab in critically ill patients with COVID-19: a quasi-experimental study. medRxiv 2020.
   Google Scholar
• Gokhale Y, Mehta R, Karnik N, et al. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia. EClinicalMedicine 2020;24:24.
   Google Scholar
• Rojas-Marte G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study. QJM. 2020;113(8):546–550. .
   PubMed Web of Science ®Google Scholar
• Roumier M, Paule R, Matthieu G, et al. Interleukin-6 blockade for severe COVID-19. medrxiv 2020.
   Google Scholar
• Klopfenstein T, Zayet S, Lohse A, et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infectious Dis. 2020;99:491–495.
   PubMed Web of Science ®Google Scholar
• Rossotti R, Travi G, Ughi N, et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect. 2020;81(4):e11–e17. .
   PubMed Web of Science ®Google Scholar
• Ramaswamy M, Mannam P, Comer R, et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: a case–control study. medrxiv. 2020.
   PubMedGoogle Scholar
• Ramiro S, Mostard RL, Magro-Checa C, et al. A Pseudo-Randomised Comparison of a Strategy with Intense Immunosuppression vs. Supportive Care Only in Patients with COVID-19-Associated Cytokine Release Syndrome Results of the CHIC-Study. SSRN Electronic Journal. 2020. DOI:10.2139/ssrn.3627257.
   Google Scholar
• Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Médecine et Maladies Infectieuses. 2020;50(5):397–400.
   Google Scholar
• Menzella F, Fontana M, Salvarani C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020;24(1):1–9. .
   PubMed Web of Science ®Google Scholar
• Nasa P, Singh A, Upadhyay S, et al. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: retrospective Study of Two Centers. Indian J Crit Care Med. 2020;24(9):771. .
   PubMed Web of Science ®Google Scholar
• Okoh AK, Bishburg E, Grinberg S, et al. Tocilizumab use in COVID-19-associated pneumonia. J Med Virol. 2021;93(2):1023–1028. .
   PubMed Web of Science ®Google Scholar
• Pettit NN, Nguyen CT, Mutlu GM, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID‐19. J Med Virol. 2021;93(3):1459-1464.
   Google Scholar
• Hashimoto S, Kitajima H, Arai T, et al. A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration. medRxiv. 2020.
   Google Scholar
• Conrozier T, Lohse A, Balblanc J-C. et al. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clinical and experimental rheumatology. 2020;38(4):742–747.
   Google Scholar
• Rimland CA, Morgan CE, Bell GJ, et al. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv. 2020.
   Google Scholar
• Morrison AR, Johnson JM, Griebe KM, et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Journal of autoimmunity. 2020;114:102512.
   Google Scholar
• Sirimaturos M, Gotur DB, Patel SJ, et al. Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients. Critical Care Explorations. 2020;2(10):10. .
   Google Scholar
• Jordan SC, Zakowski P, Tran HP, et al. Compassionate use of tocilizumab for treatment of SARS-CoV-2 pneumonia. Clinical Infectious Diseases. 2020;71(12):3168–3173. .
   Web of Science ®Google Scholar
• Gorgolas M, Cabello A, Perez LP, et al. Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late. medRxiv. 2020.
   Google Scholar
• Strohbehn GW, Heiss BL, Rouhani SJ, et al. COVIDOSE: a Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia. Clinical pharmacology and therapeutics. 2020;109(3), 688–696.
   Google Scholar
• Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et a Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. medRxiv. 2020.
   Google Scholar
• Corominas H, Castellví I, Pomar V, et al. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: covizumab-6 observational cohort. Clinical Immunology (Orlando, Fla.). 2021;223:108631.
   PubMed Web of Science ®Google Scholar
• Vu CA, DeRonde KJ, Vega AD, et al. Effects of Tocilizumab in COVID-19 patients: a cohort study. BMC infectious diseases. 2020;20(1):1–10.
   Google Scholar
• Quartuccio L, Sonaglia A, Pecori D, et al. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: a possible indication for deeper targeting of IL-6. Journal of Medical Virology. 2020;92(11):2852–2856. .
   PubMed Web of Science ®Google Scholar
• Morena V, Milazzo L, Oreni L, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. European Journal of Internal Medicine. 2020;76(36–42):36–42. .
   PubMedGoogle Scholar
• Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clinical and Experimental Rheumatology. 2020;38(3):529–532.
   PubMed Web of Science ®Google Scholar
• Patel A, Shah K, Dharsandiya M, et al. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: a retrospective cohort study. Indian Journal of medical microbiology. 2020;38(1):116–122.
   Google Scholar
• De Cáceres C, Martínez R, Bachiller P, et al. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. Pharmacological Reports: PR. 2020;72(6):1529–1537. .
   PubMed Web of Science ®Google Scholar
• Capo A, Patel H, Rajaratnam N, et al. The use of tocilizumab at a community hospital during the COVID-19 pandemic in the epicenter of northern New Jersey. Chest. 2020;158(4):A2430.
   Google Scholar
• Dastan F, Nadji SA, Saffaei A, et al. Tocilizumab administration in a refractory case of COVID-19. International Journal of Antimicrobial Agents. 2020;56(2):106043. .
   PubMed Web of Science ®Google Scholar
• Petrak RM, Skorodin NC, Van Hise NW, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with sARS‐CoV‐2. Clinical and Translational Science. 2020. DOI:10.1111/cts.12894.
   PubMed Web of Science ®Google Scholar
• Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. medRxiv. 2020.
   Google Scholar
• Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study.Expert Review of Anti-infective Therapy. 2021;19(1):93–100. .
   PubMed Web of Science ®Google Scholar
• Fernández‐Ruiz M, López‐Medrano F, Pérez‐Jacoiste Asín MA, et al. Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study. Journal of Medical Virology. 2021;93(2):831–842. .
   PubMed Web of Science ®Google Scholar
• Alattar R, Ibrahim TB, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. Journal of medical virology. 2020;92(10):2042-2049.
   Google Scholar
• Knorr JP, Colomy V, Mauriello CM, et al. Tocilizumab in patients with severe COVID‐19: a single‐center observational analysis. Journal of Medical Virology. 2020;92(11):2813–2820. .
   PubMed Web of Science ®Google Scholar
• Jiménez-Brítez G, Ruiz P, Soler X. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Medicina Clínica. 2020;155(9):410-411.
   Google Scholar
• Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. Chest. 2020;158(4):1397–1408. .
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID‐19: a single center experience. Journal of Medical Virology. 2020;92(7):814–818. .
   PubMed Web of Science ®Google Scholar
• Nasir N, Mahmood SF, Habib K, et al. Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist Tocilizumab: a tertiary care experience from Pakistan. medRxiv. 2020.
   Google Scholar
• Khan F, Stewart I, Fabbri L, et al. A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19. medRxiv. 2020.
   Google Scholar
• Rubio-Rivas M, Mora-Lujan JM, Montero A, et al. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis. medRxiv 2020.
   Google Scholar
• Kotak S, Khatri M, Malik M, et al. Use of Tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence. Cureus 2020;12(10):10. .
   Web of Science ®Google Scholar
• Zhao M, Lu J, Tang Y, et al. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol. 2021;77(3):311–319.
   Google Scholar
• Sarfraz A, Sarfraz Z, Sarfraz M, et al. Tocilizumab and COVID-19: a Meta-Analysis of 2120 Patients with Severe Disease and Implications for Clinical Trial Methodologies. Turkish journal of medical sciences.;2020. 10.3906/sag-2010-131
   Google Scholar
• Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clinical Microbiology and Infection. 2020;27(2):215–227. .
   PubMed Web of Science ®Google Scholar
• Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID‐19: a systematic review and meta‐analysis. Journal of Medical Virology. 2020;93(3):1620–1630. .
   Web of Science ®Google Scholar
• Salvati L, Occhipinti M, Gori L, et al. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. Immunol Lett. 2020;228:122–128.
   PubMed Web of Science ®Google Scholar
• Li Z, Che Q, Li M, et al. Efficacy and Safety of Tocilizumab in Patients with COVID-19: a Systematic Review and Meta-Analysis. Research Square. 2020.
   Google Scholar
• Malgie J, Schoones JW, Pijls BGJCID. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clinical Infectious Diseases. 2020. 10.1093/cid/ciaa1445
   Google Scholar
• Frigault MJ, Nikiforow S, Mansour MK, et al. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood J Am Soc Hematol. 2020;136(1):137–139.
   Google Scholar
• Shrier I, Boivin J-F, Steele RJ, et al., Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 166(10): 1203–1209. 2007. .
   PubMed Web of Science ®Google Scholar